Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GOT1 | P17174 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499780 | 0.81 | KDM4E (0.46) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL30523852 | 0.80 | KDM4E (0.55) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL1673296 | 0.80 | KDM4E (0.55) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL6761566 | 0.75 | KDM4E (0.43) | RAB9ANPC1KDM4ELMNACYP3A4 | |
| SCHEMBL9265475 | 0.73 | KDM4E (0.36) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL5568042 | 0.73 | KDM4E (0.41) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL13911023 | 0.73 | KDM4E (0.52) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL10640426 | 0.72 | KDM4E (0.38) | RAB9ANPC1KDM4ELMNATP53 | |
| SCHEMBL184194 | 0.71 | KDM4E (0.38) | RAB9ANPC1KDM4ELMNAALDH1A1 | |
| SCHEMBL297092 | 0.71 | CYP1A2 (0.50) | RAB9ANPC1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541408-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8507479-B2 | — | — | 2013-08-13 | — | — | US | disclosed |
| EP-1545512-B1 | Gold (III) complexes as anti-tumor and anti-HIV agents | UNIV HONG KONG (CN) | 2013-03-20 | — | — | EP | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-1545512-A4 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | UNIV HONG KONG (CN) | 2008-07-02 | — | — | EP | disclosed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | disclosed |
| EP-1545512-A1 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | The University of Hong Kong (CN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | disclosed |
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | CHE CHI-MING (CN) | 2004-04-01 | — | — | US | disclosed |
| WO-2004024146-A1 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | RAB9A 3119/4885NPC1 1548/4885KDM4E 3353/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | RAB9A 4588/4885NPC1 1189/4885KDM4E 1689/4885 |
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | HCCS, ME3, IDH1 | RAB9A 3888/4885NPC1 2299/4885KDM4E 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.